India Markets open in 9 hrs 7 mins

MPX International Corporation (MPXI.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.11000.0000 (0.00%)
As of 2:15PM EDT. Market open.
Full screen
Previous close0.1100
Open0.1150
Bid0.0900 x 0
Ask0.1150 x 0
Day's range0.1100 - 0.1150
52-week range0.0800 - 0.5700
Volume6,162
Avg. volume45,250
Market cap15.584M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.0860
Earnings date02-Mar-2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • MPX International’s Wholly-Owned Subsidiary, Canveda Inc., Enters Into an Agreement for the Manufacturing and Distribution of Cannabis Products in Israel
    GlobeNewswire

    MPX International’s Wholly-Owned Subsidiary, Canveda Inc., Enters Into an Agreement for the Manufacturing and Distribution of Cannabis Products in Israel

    Salus BioPharma Canveda’s medical cannabis brandNOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS.TORONTO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- MPX International Corporation (“MPX International”, “MPXI” or the “Corporation”) (CSE:MPXI; OTCQX:MPXOF), a multinational diversified cannabis company, is pleased to announce that its wholly-owned subsidiary, Canveda Inc. (“Canveda”), a licence holder under the Cannabis Act (Canada), has entered into a production and distribution agreement with Panaxia Pharmaceutical Industries Israel Ltd. (“Panaxia”), the largest manufacturer and distributor of medical cannabis products in Israel, for the packaging and distribution of cannabis which will be marketed and sold in Israel under Canveda’s medical brand “Salus BioPharma”.“MPXI has a long-standing relationship with Panaxia and welcomes the opportunity to market our brand in Israel as part of our international cannabis strategy,” noted W. Scott Boyes, Chairman, President and CEO of MPX International. “Panaxia is a major player in the Israeli market and an emerging participant in the global cannabis space and we are honored to be able to work with them on this initial project.”A first shipment of 100 kg of high-quality cannabis flower will be shipped from Canada to Israel as soon as an export permit from Health Canada is acquired. All the required import permits from Israel have been issued.Panaxia uses high-quality cannabis flower to manufacture and distribute a variety of standardized, pharma-grade, smokeless, measured dosage cannabinoid-based products including sublingual tablets, slow release tablets, pastilles, rectal suppositories, vaginal suppositories, skincare ointments, topical patches and oral spray inhalers.The Salus BioPharma products will be sold to patients with a variety of conditions such as PTSD, chronic pain, cancer, epilepsy, Parkinson’s, Alzheimer’s, anorexia and HIV/AIDS.“We are proud to work on this project with our Canadian partners MPX International Corporation and expand our collaboration to the Israeli market. As an experienced pharmaceutical company and the largest manufacturer and distributor of medical cannabis products in Israel, we are committed to providing premium, standardized, and scientifically-backed pharmaceutical cannabis products to our partners and patients worldwide. MPXI leads the pharmaceutical approach to medical cannabis in Canada, which makes them a natural partner for distribution of high-quality pharmaceutical cannabis products in Israel,” said Assi Rotbart, GM of Panaxia.“We will be shipping our initial 100 kg of bulk high-quality Sativa and Indica cannabis strains to test the market in Israel. Panaxia will be responsible for quality control, packaging and distribution of Salus BioPharma products,” said Michael Arnkvarn, COO, Canada of MPXI. “The Salus BioPharma brand is our premier medical brand and we are excited to commence international distribution of our Salus BioPharma products with Panaxia in Israel. Following this initial foray into the international cannabis market, we are working to expand distribution of the Salus BioPharma Brand to additional international markets.”About MPX International CorporationMPX International Corporation is a multinational diversified cannabis company focused on developing and operating assets across the international cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient. With current operations spanning four continents in Canada, Switzerland, South Africa, Malta and Australia as well as evolving partnership and distribution opportunities in other jurisdictions, MPXI continues to position itself as an emergent global participant in the cannabis industry.About Panaxia Pharmaceutical Industries IsraelPanaxia Labs Israel, Ltd. is a publicly traded company (TASE:PNAX.TA). It is the largest Israeli manufacturer and home-delivery distributor of medical cannabis products, and the first to have received the approval of the Israeli Ministry of Health for the manufacturing of medicinal cannabis-based pharmaceuticals (under the IMC-GMP directive) as well as EU-GMP standard certification required for commercial production and export of medical cannabis and its products to Europe. The company manufactures over 30 hemp-based medicinal products and has accumulated a broad foundation of clinical experience based on tens of thousands of patients.Panaxia is a subsidiary of the Segal Pharma Group, owned by the Segal family and founded over forty years ago. The company manufactures over 600 different pharmaceutical products that are distributed in over 40 countries worldwide. Panaxia Labs Israel is a subsidiary of Panaxia Pharmaceutical Industries, co-founded by Dr. Dadi Segal, Dr. Eran Goldberg, and Adv. Assi Rotbart as the cannabis division of the Segal Pharma Group. A sister subsidiary, Panaxia US, manufactures in North America over 60 hemp-based medicinal products, including sublingual tablets, lozenges, oils, and inhalators designed for treating conditions such as PTSD, cancer, chronic pain, epilepsy, anorexia, burns, and many other ailments. Panaxia Group has over 150 employees, who also conduct all of its clinical trials.Cautionary Statement Regarding Forward-Looking InformationThis news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX International’s objectives and intentions.  Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX International’s public documents filed on SEDAR at www.sedar.com, including its audited annual consolidated financial statements for the financial years ended September 30, 2019 and 2018 and the corresponding annual management’s discussion and analysis; and other matters discussed in this news release. Although MPX International believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX International disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.For further information, please contact:MPX International Corporation W. Scott Boyes, Chairman, President and CEO T: +1-416-840-4703 info@mpxinternationalcorp.com http://mpxi.tv For additional information on MPXI visit our website www.mpxinternationalcorp.com or http://mpxi.tv.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5173bd31-6e4b-41a7-8943-08a39e692c2f

  • GlobeNewswire

    MPX International’s Wholly-Owned Subsidiary, Canveda Inc., Enters Into a Purchase Agreement With Zenabis Ltd. for the Supply of Cannabis

    NOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS.TORONTO, Aug. 12, 2020 (GLOBE NEWSWIRE) -- MPX International Corporation (“MPX International”, “MPXI” or the “Corporation”) (CSE:MPXI; OTCQX:MPXOF), a multinational diversified cannabis company, is pleased to announce that its wholly-owned subsidiary, Canveda Inc. (“Canveda”), a licence holder under the Cannabis Act (Canada), has entered into a purchase agreement for high quality cannabis flower from Zenabis Global Inc (“Zenabis”), a large scale Canadian producer with an estimated 96,400 kg of licensed cannabis cultivation space.“MPX International has a strong presence in the international cannabis market and we have identified several international opportunities that are interested in purchasing Canadian cannabis. This, combined with  the growth of our domestic medical cannabis  projects, our recent Canadian retail distribution agreements in Alberta and Saskatchewan as well as our developing international marketing initiatives require us to partner with a large scale Canadian producer in order to fulfill our product needs,” noted Michael Arnkvarn COO Canada of MPXI. “We were introduced to Zenabis as a potential partner and have been  impressed by the magnitude and quality of products that they have to offer.”The supply agreement between the parties secures Canveda 300 – 1,000 kg of cannabis flower per calendar quarter. The initial shipment of 100 kg will be sent to Israel as soon as an export permit from Health Canada is acquired. All the required import permits from Israel have been issued.Daniel Burns, Chair of the Board of Directors of Zenabis, stated, "We are excited to formalize our partnership with MPXI, and we look forward to being a strong, consistent partner in ongoing cannabis delivery."“We welcome the arrangement with a quality producer like Zenabis,” stated W. Scott Boyes, Chairman, President and CEO of MPX International. “This agreement is consistent with our strategy of acting as an intermediary between Canadian cannabis license holders and the domestic and international markets. Internationally, we are working to expand distribution of the Salus BioPharma brand to additional international markets, following on our initial foray into the international cannabis market with the arrangement with Panaxia Pharmaceutical Industries Ltd. in Israel, we are working to expand distribution to additional international markets. Domestically, we are making great strides to advance revenues of our Canadian operations. Canveda has entered into supply agreements with the Provincial Governments of Alberta and Saskatchewan to supply high quality flower. Our wholly-owned Spartan Wellness Corporation, is using our Medical Cannabis Learning Network (the “MCLN”) to connect military veterans and first responders to Canveda through the Spartan Network (https://spartannetwork.ca) and has entered into a services agreement with Medical Cannabis by Shoppers Drug Mart Inc., a subsidiary of Shoppers Drug Mart, to utilize its network of volunteers and professionals to perform clinical services for Shopper Drug Mart patients. We have also been engaged by and Miramedia Retail Inc. to jointly develop the MiraCBD portal and for Miramedia to utilize with retailers, natural health practitioners and consumers to connect their customers to the MCLN platform. We think that these developments, amongst other initiatives that we are working on both in Canada and abroad will drive an increase of shareholder value as the disruptions from COVID-19 begin to ease.”About MPX International CorporationMPX International Corporation is a multinational diversified cannabis company focused on developing and operating assets across the international cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient. With current operations spanning four continents in Canada, Switzerland, South Africa, Malta and Australia as well as evolving partnership and distribution opportunities in other jurisdictions, MPXI continues to position itself as an emergent global participant in the cannabis industry.About Zenabis Ltd.Zenabis (TSX: ZENA) is a significant Canadian licensed cultivator of medical and recreational cannabis, Zenabis is a significant Canadian licensed cultivator of medical and recreational cannabis, and a propagator and cultivator of floral and vegetable products. Zenabis employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta, Aldergrove, Pitt Meadows and Langley, British Columbia; and Stellarton, Nova Scotia. Zenabis currently has 96,400 kg of licensed cannabis cultivation space and four licensed facilities. Zenabis has 3.5 million square feet of total facility space dedicated to a mix of cannabis production and cultivation and its non-cannabis propagation and floral business.Zenabis expects its Zenabis Atholville, Zenabis Stellarton and Zenabis Langley facilities to be in steady state production in 2020. The Zenabis brand name is used in the cannabis medical market, the Namaste, Blazery, and Re-Up brand names are used in the cannabis adult-use recreational market, and the True Büch brand name is used for Zenabis’ kombucha products.Cautionary Statement Regarding Forward-Looking InformationThis news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX International’s objectives and intentions.  Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX International’s public documents filed on SEDAR at www.sedar.com, including its audited annual consolidated financial statements for the financial years ended September 30, 2019 and 2018 and the corresponding annual management’s discussion and analysis; and other matters discussed in this news release. Although MPX International believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX International disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.For further information, please contact:MPX International Corporation W. Scott Boyes, Chairman, President and CEO T: +1-416-840-4703 info@mpxinternationalcorp.com http://mpxi.tvFor additional information on MPXI visit our website www.mpxinternationalcorp.com or http://mpxi.tv.

  • MPX International Introduces Canadian Retail Brand, Strain Rec™ to be Used by Its Wholly-Owned Subsidiary, Canveda Inc., a Licence Holder Under the Cannabis Act (Canada)
    GlobeNewswire

    MPX International Introduces Canadian Retail Brand, Strain Rec™ to be Used by Its Wholly-Owned Subsidiary, Canveda Inc., a Licence Holder Under the Cannabis Act (Canada)

    Strain Rec™ MPX International Introduces Canadian Retail Brand, Strain Rec™ to be Used by Its Wholly-Owned Subsidiary, Canveda Inc., a Licence Holder Under the Cannabis Act (Canada)Announces First Shipments to SaskatchewanNOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS.TORONTO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MPX International Corporation (“MPX International”, “MPXI” or the “Corporation”) (CSE:MPXI; OTCQX:MPXOF), a multinational diversified cannabis company, is pleased to announce the launch of its Canadian recreational brand, Strain Rec ™ by its wholly-owned subsidiary Canveda Inc. (“Canveda”) with initial shipments made to the Province of Saskatchewan. For additional information on Strain Rec ™ visit the website www.strainrec.ca.“Canveda has introduced its unique Canadian recreational brand Strain Rec ™. Brand recognition is pivotal to success in the marketplace and we are pleased to have been able to develop a brand concept which will be representative of the recreational market,” said Michael Arnkvarn, Chief Operating Officer, Canada of MPXI. “We received positive initial feedback on our first shipment and have since followed up with a second shipment which was sent to the distributor in July.”The initial Strain Rec ™ offering by Canveda consists purely of flower and was introduced to eight (8) Saskatchewan retailers during the last week of June by its Saskatchewan-approved distributor.“This is our initial salvo into the Canadian recreational marketplace and we believe that we are in a strong position to succeed. The adult use market demands differentiated products that contain high THC levels and our Canveda facility is able to offer unique strains that meet that demand,” noted W. Scott Boyes, Chairman, President and CEO of MPX International. “Saskatchewan is a relatively small market with only a little over 50 stores, making this province a great place for MPXI to test the waters. As we expand our offerings to include extracts, topicals and edibles, the revenues generated by the recreational market will become an integral component of MPXI’s Canadian growth strategy.”MPXI is also developing distribution channels for the Strain Rec™ brand with additional provincial cannabis marketing boards and will inform its shareholders of these developments in due course.About MPX International CorporationMPX International Corporation is a multinational diversified cannabis company focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.Cautionary Statement Regarding Forward-Looking InformationThis news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX International’s objectives and intentions.  Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX International’s public documents filed on SEDAR at www.sedar.com, including its audited annual consolidated financial statements for the financial years ended September 30, 2019 and 2018 and the corresponding annual management’s discussion and analysis; and other matters discussed in this news release. Although MPX International believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX International disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.For further information, please contact:MPX International Corporation W. Scott Boyes, Chairman, President and CEO T: +1-416-840-4703 info@mpxinternationalcorp.com http://mpxi.tvFor additional information on MPXI visit our website www.mpxinternationalcorp.com or http://mpxi.tv.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/45008bc6-0183-4ccb-b79b-f19754d25823